Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
Study launched earlier this year is expected to confirm previous efficacy signal in 2L KRAS-mutant MSS colorectal cancer study that saw 17 months PFS vs.
6 months for the historical standard of care SAN DIEGO, Oct.
20, 2
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.